MJJ Biotech

Guangdong Maijinjia Biotechnologies Co., Ltd. (registered capital of 15,431,944 RMB), established on August 14, 2019, is a China-Denmark joint venture innovative technology enterprise specializing in antisense nucleic acid drugs, with an international perspective. It has received investment from the industrial fund of Huangpu District Government of Guangzhou City. The company possesses Blockmir nucleic acid drug development technology and Dosevo nucleic acid drug screening technology, both protected by a comprehensive patent portfolio, and owns global rights to all related patents. The core team has over several decades of biopharmaceutical R&D and entrepreneurial experience in the fields of small molecule RNAs, modified oligonucleotide patents, clinical trials, biotechnology, and business management.Focus areas: Utilizing Blockmir technology to address unmet clinical needs for "central nervous system, ophthalmology, liver diseases, cardiovascular diseases, and respiratory diseases" that current marketed drugs cannot satisfy.